MetaCap

Penumbra Inc. (PEN)

NYSE: PENHealth CareMedical/Dental InstrumentsUSD

319.12-0.89 (-0.28%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

PEN stock chart

Technical analysis

Key statistics

All statistics
Market cap
$12.58B
52-week range
284.95 – 362.41
Day range
319.02 – 320.32
Volume / Avg
205.41K / 358.21K
Beta
—

52-week range

$284.95$362.41

PEN stock today

Shares of Penumbra (PEN) finished lower on Nov 20 at $319.12, a drop of 0.28% or $0.89 per share, versus the S&P 500's 3.70% decline. Shares are 11.9% below their 52-week high of $362.41, set on Jan 21, 2026 and 12.0% above the 52-week low of $284.95, in the middle of the past year's range. PEN is up 2.6% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 10.6%.

At 80.4x trailing earnings, Penumbra trades above the peer-group median of 42.4x. Its forward P/E of 53.1x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Penumbra

Company profile

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands.

Industry
Medical/Dental Instruments
CEO
Mr. Adam Elsesser J.D.
Headquarters
Alameda, CA
Employees
4,700
IPO year
2015

Financial highlights

Full financials

In fiscal 2025, Penumbra generated $1.40 billion in revenue, up 17.5% from fiscal 2024, its 12th consecutive year of revenue growth. Net income was $177.7 million (+1168.1% year over year), for a net margin of 12.7% versus a median of 0.7% in the prior 5 years. Gross margin was 67.1% (up from 63.2%) and operating margin 13.5%.

Penumbra annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$1.40B$1.19B$1.06B$847.13M$747.59M
Growth+17.50%+12.86%+24.95%+13.32%+33.40%
Net income$177.69M$14.01M$90.95M$-2.00M$5.28M
EPS (diluted)$4.52$0.36$2.32$-0.05$0.14

Analyst forecast

Forecast

Consensus (17 analysts)

hold

Avg. price target

$362.54+13.61%

  • Strong buy 1
  • Buy 2
  • Hold 14
  • Sell 0
  • Strong sell 0

Target range

Low $320.00High $374.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$1.07 vs —

PEN news

All PEN news

Penumbra peers

Health Care sector
PEN peer companies
CompanyPrice% ChgMarket capCompare
BAXBaxter International Inc.25.390.00%$13.14Bvs PEN
GKOSGlaukos Corporation237.31-0.33%$14.05Bvs PEN
SOLVSolventum Corporation84.50-1.52%$14.36Bvs PEN
PODDInsulet Corporation133.17-2.96%$9.24Bvs PEN
GMEDGlobus Medical Inc. Class A66.89-2.49%$8.86Bvs PEN
TFXTeleflex Incorporated161.58-1.11%$6.41Bvs PEN
HAEHaemonetics Corporation120.16-0.17%$5.47Bvs PEN
MMSIMerit Medical Systems Inc.84.34-0.08%$5.05Bvs PEN

Indexes, lists and sector

Penumbra stock FAQ

What is Penumbra's stock price today?

PEN last traded at $319.12 as of Nov 20, 4:00 PM EST, down 0.28% on the day. Prices are delayed at least 15 minutes.

What is PEN's P/E ratio?

PEN trades at a trailing P/E ratio of 80.38 and a forward P/E of 53.09, compared with a median of 42.4 for its closest peers.

Who is Penumbra's CEO?

Mr. Adam Elsesser J.D. is the chief executive officer of Penumbra Inc., which has about 4,700 employees.

What is the PEN 52-week high?

The 52-week high for PEN is $362.41 and the 52-week low is $284.95. The stock is currently 11.9% below its high.

Compare PEN